PubAg

Main content area

Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

Author:
Zhang, Xuefeng, Wang, Jing, Lu, Jing, Li, Rongrong, Zhao, Shuli
Source:
Virology journal 2018 v.15 no.1 pp. 137
ISSN:
1743-422X
Subject:
Hepatitis B virus, Primates, immunogenicity, safety assessment, vaccines
Abstract:
Ad-HBV is a product (T101) aiming to treat chronic HBV firstly developed by Transgene S.A., France then by Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China in China.
Agid:
6117146